BioSpace News Archive

July 9, 2024

Obesity

Lilly’s Mounjaro Helps Patients Lose More Weight Than Novo’s Ozempic: Study

Eli Lilly’s Mounjaro outperformed Novo Nordisk’s Ozempic at inducing weight loss in obese or overweight adults, according to an observational study published Monday in JAMA Internal Medicine.

July 9, 2024

·

2 min read

·

Tristan Manalac

Sign in front of Pfizer in Quebec, Canada

Business

Pfizer CSO Mikael Dolsten to Step Down After 15 Years Driving R&D

The pharma giant announced Tuesday that Mikael Dolsten is leaving his role as chief science officer after more than 15 years. Pfizer is conducting an external search for a replacement with Dolsten staying on to assist in finding his replacement over next several months.

July 9, 2024

·

1 min read

·

Kate Goodwin

Pictured: Roche Diagnostics building in California

Regulatory

Roche Reintroduces Wet AMD Eye Implant Nearly Two Years After Voluntary Recall

Roche’s eye implant Susvimo for patients with neovascular age-related macular degeneration is re-entering the U.S. market after the FDA approved updates to the components of the product.

July 9, 2024

·

2 min read

·

Tristan Manalac

Pictured: Novo Nordisk's corporate headquarters in Denmark

Weight Loss

What Does Wegovy’s Launch in China Mean as Biosimilar Competition Emerges?

As Novo Nordisk’s weight loss drug enters the Chinese market, its patent is expiring in two years and biosimilar competition is rising.

July 9, 2024

·

2 min read

·

Tyler Patchen

Pictured: uniQure headquarters in Amsterdam

Huntington’s Disease

UniQure Wins First FDA RMAT in Huntington’s Disease After Strong Phase I/II Data

Following a disappointing readout last year, uniQure on Tuesday posted promising Phase I/II data for its investigational gene therapy AMT-130 and nabbed the first-ever Regenerative Medicine Advanced Therapy designation from the FDA in Huntington’s disease.

July 9, 2024

·

2 min read

·

Tristan Manalac

Gilead's corporate headquarters in Silicon Valley

Policy

US Government Files Appeal in High-Stakes HIV PrEP Patent Battle Against Gilead

The Biden administration is appealing a 2023 jury decision that declared invalid its patent protections over Gilead Sciences’ HIV prevention regimen of Truvada and Descovy.

July 9, 2024

·

2 min read

·

Tristan Manalac

Pictured: A close-up of the U.S. Capitol dome/iSto

Policy

House Speaker Plans to Vote, Pass BIOSECURE Act into Law This Year

House Speaker Mike Johnson (R-La.) on Monday said he intends to have a “significant package of China-related legislation” signed into law by the end of this year, including the BIOSECURE Act which intends to stop federal contracts with Chinese “companies of concern.”

July 9, 2024

·

2 min read

·

Tyler Patchen

Policy

PBMs ‘Wield Enormous Power’ Over Patient Access to Affordable Drugs: FTC

The Federal Trade Commission on Tuesday issued an interim report on the top pharmacy benefit managers, showing that they are generating massive profit at the expense of patients by inflating prescription drug costs.

July 9, 2024

·

2 min read

·

Tyler Patchen